Veracyte (VCYT) Expected to Announce Earnings on Wednesday

Veracyte (NASDAQ:VCYT) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect Veracyte to post earnings of $0.21 per share and revenue of $110.81 million for the quarter.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.29 by $0.07. The company had revenue of $118.63 million for the quarter, compared to the consensus estimate of $110.73 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. During the same quarter last year, the firm posted ($0.39) EPS. On average, analysts expect Veracyte to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Veracyte Price Performance

Veracyte stock opened at $30.35 on Monday. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -202.33 and a beta of 2.14. The firm has a 50-day moving average of $31.42 and a two-hundred day moving average of $37.24. Veracyte has a 1 year low of $19.73 and a 1 year high of $47.32.

Wall Street Analyst Weigh In

Several research firms have commented on VCYT. Stephens restated an “overweight” rating and set a $45.00 price objective on shares of Veracyte in a report on Wednesday, March 26th. Craig Hallum started coverage on Veracyte in a research note on Thursday, March 20th. They set a “buy” rating and a $45.00 price target on the stock. UBS Group upped their price objective on shares of Veracyte from $46.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. StockNews.com downgraded shares of Veracyte from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Finally, Guggenheim dropped their price objective on shares of Veracyte from $45.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Veracyte presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.